

# Advantagene to present at the 16<sup>th</sup> Annual Needham Healthcare Conference

**AUBURNDALE, MA (April 3, 2017)** - Advantagene, Inc., a clinical-stage biotechnology company developing a novel cancer immunotherapy platform for the treatment of solid tumors, announced today that Stephen Rocamboli, Chief Business Officer, will present at the 16<sup>th</sup> Annual Needham Healthcare Conference on April 4, 2017, at 9:40 a.m. EST, at the Westin Grand Central Hotel, New York, New York.

## **About Advantagene, Inc.**

Advantagene is a Massachusetts based biotechnology company developing its proprietary Gene Mediated Cytotoxic Immunotherapy (GMCI™) technology for the treatment of solid tumors. GMCI™ is an “off the shelf” low toxicity immunotherapy that stimulates a patient’s own immune system to generate a robust response against his or her cancer, causing tumor cell death and clearance. Advantagene is conducting a registration clinical trial with its lead clinical candidate, ProstAtak®, for the treatment of newly diagnosed prostate cancer patients under a Special Protocol Assessment issued by the U.S. Food and Drug Administration. If approved, ProstAtak® will be the first and only pharmaceutical intervention available for these patients. The company is conducting additional clinical studies using GMCI™ to treat lung, pancreas and brain cancer with impressive clinical results to date. For more information about Advantagene and our GMCI™ cancer immunotherapy program please visit [www.advantagene.com](http://www.advantagene.com).

## **Forward-Looking Statements**

This news release contains forward-looking statements, including, but not limited to: statements regarding Advantagene’s plans and ability to develop its GMCI™ technology to safely and effectively treat cancer. These forward-looking statements are subject to a number of risks. Advantagene undertakes no obligation to update these forward looking statements and you are cautioned not to place undue reliance on any of these forward looking statements. For more information about our company, please visit [www.advantagene.com](http://www.advantagene.com) or send an email to [info@advantagene.com](mailto:info@advantagene.com).

## Contact

Media & Investor Relations  
Advantagene, Inc.  
440 Lexington Avenue  
Auburndale, MA 02466  
(617) 916-5445  
[info@advantagene.com](mailto:info@advantagene.com)  
Released April 03, 2017